News | SCAI | June 01, 2023

Ticogrelor Monotherapy Post PCI Associated with Similar Rates of Revascularization as Duel Antiplatelet Therapy

Analysis of TWILIGHT trial shines light on Effect of Therapies following percutaneous coronary intervention 

Analysis of TWILIGHT trial shines light on Effect of Therapies following percutaneous coronary intervention

Getty Images


June 1, 2023 — New insights from the TWILIGHT trial showed that ticagrelor monotherapy after three months of ticagrelor plus aspirin was associated with similar rates of recurrent coronary revascularization, major adverse cardiac and cerebrovascular events (MACCE) and a lower risk of net adverse clinical events (NACE) compared with duel antiplatelet therapy (DAPT). The results from the randomized control trial of more than 7,000 patients were presented as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2023 Scientific Sessions. 

Despite advances in percutaneous coronary intervention (PCI) techniques, devices and secondary prevention, repeat revascularization remains a concern and is associated with increased morbidity, hospitalization and healthcare costs. 

In the TWILIGHT trial, high-risk patients who were event-free and adherent to a ticagrelor-based DAPT for three months after PCI were randomized to ticagrelor plus aspirin or ticagrelor plus placebo for 12 additional months. The primary endpoint was repeat revascularization due to recurrent or persistent symptomatic myocardial ischemia. Secondary endpoints included target lesion revascularization (TLR), target vessel revascularization (TVR) and major adverse cardiac and cerebrovascular events (MACCE) and net adverse clinical events (NACE). All endpoints were adjudicated and assessed at 12 months after randomization in the per-protocol population. 

Among 7,039 patients, ticagrelor monotherapy and ticagrelor plus aspirin were associated with a similar risk of repeat revascularization (7.1% vs 6.6%, HR 1.09, 95% CI 0.90-1.30), TLR, TVR and MACCE, while NACE was lower with ticagrelor monotherapy.  The results also showed that clinically-driven revascularization was associated with an excess risk for subsequent death, myocardial infarction or stroke (aHR 2.92, 95% CI 1.82 – 4.67). 

“In high-risk PCI patients, it’s critical to lessen the occurrence of repeat revascularization,” said Usman Baber, M.D., Associate Professor of Medicine at the University of Oklahoma Health Sciences Center, and lead author of the study. “The findings presented today from the TWILIGHT trial provide a greater understanding of the impact of DAPT and ticagrelor monotherapy following PCI for the clinical community.” 

For more information: www.scai.org 

 

Find more SCAI23 conference coverage here 

 

Related TWILIGHT Trial Content: 

Long-term Dual Antiplatelet Therapy Benefits Reinforced in SCAI Late-breaking Study 

Shorter DAPT With Xience Stent is Noninferior to Standard DAPT 

TWILIGHT Trial Substudy Examines Bioabsorbable Polymer vs. Durable Polymer Drug-Eluting Stents in High-Risk PCI 

VIDEO: TWILIGHT Trial Shows Benefit to Ticagrelor Monotherapy After Stent Implantation 


Related Content

News | SCAI

May 3, 2025 — The Society for Cardiovascular Angiography & Interventions (SCAI) announced its new leadership for 2025–26 ...

Home May 05, 2025
Home
News | SCAI

At the SCAI 2025 Scientific Sessions in Washington, DC, SCAI President James B. Hermiller, MD, MSCAI, recognized several ...

Home May 01, 2025
Home
News | SCAI

Feb. 12, 2025 — A new study published in JSCAI has revealed a lower risk of cardiovascular events for patients with Type ...

Home February 18, 2025
Home
News | SCAI

May 7, 2024 — Medtronic announced the release of important clinical outcomes in two leading transcatheter valve ...

Home May 07, 2024
Home
News | SCAI

May 7, 2024 — Women and black patients were less frequently treated with minimally invasive therapy compared to men or ...

Home May 07, 2024
Home
News | SCAI

May 1, 2024 — The annual Society for Cardiovascular Angiography & Interventions (SCAI) kicks off its SCAI Scientific ...

Home May 01, 2024
Home
News | SCAI

May 24, 2023 — The largest interventional study focused on pulmonary embolisms highlighted importance of rapid removal ...

Home May 24, 2023
Home
Feature | SCAI | Christine Book

May 23, 2023 — The Society for Cardiovascular Angiography & Interventions (SCAI) welcomed its 46th President and 2023 ...

Home May 23, 2023
Home
News | SCAI

May 19, 2023 — Findings from a study examining the relationship between marijuana use and peripheral artery disease (PAD ...

Home May 19, 2023
Home
News | SCAI

February 7, 2023 — The Society for Cardiovascular Angiography & Interventions (SCAI) announced the second application ...

Home February 07, 2023
Home
Subscribe Now